sub:assertion {
  d:DB00517 v:identifier "DB00517" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB00517" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB00517> ;
    dv:drugbank-id "APRD00800" , "DB00517" ;
    dv:x-cas <http://bio2rdf.org/cas:80-50-2> ;
    dv:x-chebi <http://bio2rdf.org/chebi:2739> ;
    dv:x-kegg <http://bio2rdf.org/kegg:C06830> , <http://bio2rdf.org/kegg:D00232> ;
    dv:x-pharmgkb <http://bio2rdf.org/pharmgkb:PA164754880> ;
    dct:description "Anisotropine methylbromide is a quaternary ammonium compound. Its use as treatment adjunct in peptic ulcer has been replaced by the use of more effective agents. Depending on the dose, anisotropine methylbromide may reduce the motility and secretory activity of the gastrointestinal system, and the tone of the ureter and urinary bladder and may have a slight relaxant action on the bile ducts and gallbladder. In general, smaller doses of anisotropine methylbromide inhibit salivary and bronchial secretions, sweating, and accommodation; cause dilatation of the pupil; and increase the heart rate. Larger doses are required to decrease motility of the gastrointestinal and urinary tracts and to inhibit gastric acid secretion."@en ;
    dct:identifier "drugbank:DB00517" ;
    dct:title "Anisotropine Methylbromide"@en ;
    a dv:Drug ;
    rdfs:label "Anisotropine Methylbromide [drugbank:DB00517]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB00517> .
}